Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis
Status:
Terminated
Trial end date:
2018-11-29
Target enrollment:
Participant gender:
Summary
DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY
OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH DERMATOMYOSITIS